

Media Release

mylife Loop offers new remote monitoring feature for parents

Burgdorf, 22.02.2023, 7 a.m. – Parents and caregivers of children with diabetes can now follow their child's glucose and insulin data via the mylife CamAPS FX app on their own personal smartphone. The new "Companion remote monitoring" feature is fully integrated into the app. It gives parents and caregivers better control and peace of mind.

Parents get an informative overview through Companion remote monitoring within the mylife CamAPS FX app, as they can view all their child's therapy data at any time via their smartphone – regardless of whether the child is at school, enjoying his or her hobbies or meeting friends. Especially at night, remote diabetes monitoring allows a relaxed sleep and can relieve caregivers considerably. Besides the common display of Continuous Glucose Monitoring (CGM) data, also insulin delivery data, Boost & Ease-Off usage, pump information and other relevant mylife CamAPS FX information can simply be shared with parents and caregivers.

Freedom of choice with mylife Loop – rollout in further countries

mylife YpsoPump and mylife CamAPS FX is the only automated insulin delivery (AID) system that can be connected either to the Dexcom G6 sensor from Dexcom or to the FreeStyle Libre® 3 sensor from Abbott. It is designed to help people with Type 1 diabetes to better control their glucose levels and reduce the burden of daily diabetes management.

Abbott's FreeStyle Libre® 3 sensor has been compatible with mylife Loop in Germany since December 2022. This compatibility will be rolled out in Switzerland, UK and the Netherlands in the first half of 2023.

The mylife Loop offer is currently available for Android, iOS will follow.

Contact

Susanne Köhler, Public Relations, Ypsomed Holding AG
+41 34 424 47 32, susanne.koehler@ypsomed.com

Ypsomed Group

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 35 years of experience. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylife Diabetescare directly to patients or via pharmacies and hospitals as well as under YDS Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies. The company is headquartered in Burgdorf, Switzerland, and has a global network of production facilities, subsidiaries and distribution partners employing a staff of over 2,000 employees worldwide.

Ypsomed Holding AG

Brunnmattstrasse 6
3401 Burgdorf / Switzerland
www.ypsomed.com